ATE364632T1 - Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation - Google Patents

Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation

Info

Publication number
ATE364632T1
ATE364632T1 AT01123851T AT01123851T ATE364632T1 AT E364632 T1 ATE364632 T1 AT E364632T1 AT 01123851 T AT01123851 T AT 01123851T AT 01123851 T AT01123851 T AT 01123851T AT E364632 T1 ATE364632 T1 AT E364632T1
Authority
AT
Austria
Prior art keywords
human origin
antibodies
thrombocyte aggregation
inhibiting
inhibiting thrombocyte
Prior art date
Application number
AT01123851T
Other languages
English (en)
Inventor
Claudia Buettner
Meike Schwarz
Stefan Knackmuss
Karlheinz Peter
Peter Roettgen
Melvyn Little
Original Assignee
Affimed Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics Ag filed Critical Affimed Therapeutics Ag
Application granted granted Critical
Publication of ATE364632T1 publication Critical patent/ATE364632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01123851T 2001-10-05 2001-10-05 Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation ATE364632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123851A EP1300419B1 (de) 2001-10-05 2001-10-05 Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation

Publications (1)

Publication Number Publication Date
ATE364632T1 true ATE364632T1 (de) 2007-07-15

Family

ID=8178855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01123851T ATE364632T1 (de) 2001-10-05 2001-10-05 Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation

Country Status (7)

Country Link
US (1) US7812136B2 (de)
EP (1) EP1300419B1 (de)
JP (2) JP4504017B2 (de)
AT (1) ATE364632T1 (de)
DE (1) DE60128914T2 (de)
ES (1) ES2288900T3 (de)
WO (1) WO2003031476A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US8455627B2 (en) * 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8586033B2 (en) * 2003-12-03 2013-11-19 The Scripps Research Institute Integrin αIIbβ3 specific antibodies and peptides
KR20080031383A (ko) * 2005-07-05 2008-04-08 베이커 메디컬 리서치 인스티튜트 항응고제 및 그의 용도
WO2007139208A1 (ja) * 2006-05-26 2007-12-06 Kurume University 血小板の粘着凝集反応に関連する疾患の予防用又は治療用の医薬組成物、および、そのスクリーニング方法
US8563690B2 (en) 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
AU2010249470B2 (en) 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
KR101451340B1 (ko) * 2012-08-02 2014-10-15 (주)애드바이오텍 모발 생장 촉진용 조성물
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6686768B2 (ja) * 2015-09-03 2020-04-22 東ソー株式会社 細胞の分離回収方法
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
PL4218804T3 (pl) 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
HRP20230308T1 (hr) 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
EP3990116A1 (de) 2019-06-28 2022-05-04 Gensun Biopharma Inc. Antitumor-antagonist bestehend aus einer mutierten tgfss1-rii-extrazellulären domäne und einem immunoglobulin-gerüst
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU659873B2 (en) * 1991-09-17 1995-06-01 Teijin Limited Human monoclonal antibody against glycoprotein IIb/IIIa
WO1994018221A1 (en) * 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6790938B1 (en) * 1997-06-06 2004-09-14 Asat Ag Applied Science & Technology Anti-GPIIb/IIIa recombinant antibodies
PT1157041E (pt) * 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro

Also Published As

Publication number Publication date
DE60128914T2 (de) 2008-05-08
DE60128914D1 (de) 2007-07-26
EP1300419B1 (de) 2007-06-13
JP4504017B2 (ja) 2010-07-14
JP2005514009A (ja) 2005-05-19
US7812136B2 (en) 2010-10-12
JP2010029203A (ja) 2010-02-12
ES2288900T3 (es) 2008-02-01
US20070218067A1 (en) 2007-09-20
WO2003031476A1 (en) 2003-04-17
EP1300419A1 (de) 2003-04-09

Similar Documents

Publication Publication Date Title
DE60128914D1 (de) Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
BRPI0511008A (pt) agentes de ligação de il-13
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
NO2017032I1 (no) bezlotoksumab
CY1113087T1 (el) Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4
ATE461220T1 (de) Anti-egfr-antikörper
HUS1500025I1 (hu) KDR-re specifikus humán ellenanyagok és alkalmazásaik
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
MA34287B1 (fr) Compositions et méthodes d'utilisation d'anticorps multivalents thérapeutiques de faible densité de la protéine apparentée à la lipoprotéine 6 (lrp6)
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
WO2003074679A3 (en) Antibody optimization
DK1699826T3 (da) Syntetiske immunoglobulindomæner med bindende egenskaber konstrueret i regioner af molekylet forskellig fra de komplementaritets-bestemmende domæner
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
SI1557462T1 (sl) Celice monocitnega izvora, ki inducirajo sprejemljivost transplantata, kot tudi njihova priprava in uporaba
CY1116525T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
DK1875237T3 (da) Docetaxel-immunassay
WO2004046188A3 (en) Anti-activated ras antibodies
DE602005022315D1 (en) Taxol-immunoassay
EE200300092A (et) EDb-fibronektiinidomeeni retseptor
DE10108995A1 (de) Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
DE50104758D1 (de) Einrichtung zum Verbinden beweglicher Teile mit Strukturbauteilen von Flugzeugen od. dgl.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1300419

Country of ref document: EP